跳至主要内容
临床试验/NCT02940977
NCT02940977Unknown不适用

Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2016年10月1日最近更新:
适应症

试验速览

阶段
不适用
入组人数
120
试验地点
1
主要终点
Circulating tumor cell (CTC) total number and epithelial-intermediate-mesenchymal ratio detected by CTC enrichment and FISH technique

研究概览

简要总结

  1. To elucidate the role of CTC detection in the evaluation of risk level in PCa patients, and establish a mathematic model for predicting the pathological status.
  2. To explore the possible subtle change in CTC condition after radical prostatectomy.

详细描述

  1. Detect and evaluate the CTC status (a total of 3 times: 1 day before sugery, 3/12 months after surgery) for all of the PCa patients enrolled. Analyze the CTC result with PSA level, needle biopsy and radiological imaging information.
  2. Analyze the difference in CTC amount/Epithelial-Mesenchymal ratio between patients in different D'Amico risk level(low/intermediate/high).
  3. Establish a mathematic model based on the CTC results and pathological condition observed in operation (OC, organ confined; EPE, extraprostatic extension; SVI, seminal vesicle invasion; LNI, lymph node invasion), and compare this model with the latest version of Partin table.
  4. Detect and compare the CTC and PSA level 3/12 months after surgery. Evaluate the radiological condition in 12 months after blood draw.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Diagnosed with PCa by biopsy, for the first time.
  • Clinical assessed suitable for radical prostatectomy
  • Age ≥ 18 years, able to provide written informed consent
  • No prior systematic or regional treatment for PCa.
  • No neuro-endocrine differentiation or small cell PCa pattern.
  • ECOG status 0-1
  • Expected life span ≥ 12 months.
  • Multiorgan function (heart, lung, liver, kidney) able to tolerate radical prostatectomy, and meet the standard of this study.

排除标准

  • Severe concomitant disease or infection.
  • ALT or AST > 2.5 ULN, or total bilirubin > 1.5 ULN; Creatinine >177umol/L(2.5mg/dL);Plt < 100,000/uL, Neutrophil <1,500/uL.
  • Known or suspected brain metastasis or leptomeningeal carcinomatosis.
  • Another malignancy in the last 5 years, excluding completely cured melanoma.
  • Severe cardiovascular disease, including:
  • Myocardial infarct within 6 months; Uncontrolled angina pectoris within 3 months; Congestive heart failure; Ventricular arrhythmia history with clinical significance; Morbiz type Ⅱ or complete heart block
  • Major surgery (general anesthesia) within 4 weeks.

结局指标

主要结局

Circulating tumor cell (CTC) total number and epithelial-intermediate-mesenchymal ratio detected by CTC enrichment and FISH technique

时间窗: 1 day before operation

This step should be completed within the day when the peripheral venous blood is drawn.

CTC total number and epithelial-intermediate-mesenchymal ratio detected by CTC enrichment and FISH technique

时间窗: 12 months after operation

This step should be completed within the day when the peripheral venous blood is drawn.

Pathological findings (whether the patient has: 1.OC, organ confined; 2.EPE, extraprostatic extension; 3. SVI, seminal vesicle invasion; 4. LNI, lymph node invasion) during the radical prostectomy, confirmed by pathology section result

时间窗: On the day of operation

The pathology section evaluation will be done by two pathologists independently. A third pathology expert will join to make a final decision if opposite results are given by the two pathologists.

次要结局

  • Prostate specific antigen (PSA) level measurement using peripheral venous blood(6 months after operation)
  • PSA level measurement using peripheral venous blood(9 months after operation)
  • Radiological evaluation including isotope bone scanning and pelvic magnetic resonance imaging (MRI) scan(12 months after operation)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jun Qi

Head of the Urology Department

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

研究点 (1)

Loading locations...

相似试验